top of page

Narcolepsy’s Cardiovascular Consequences: A Real-World Evidence Study

An increased risk for new-onset cardiovascular events is seen among individuals with narcolepsy, reveals R. Ben-Joseph, the lead author of a groundbreaking study published in Sleep. The research, conducted using IBM® MarketScan® administrative claims data, aims to evaluate the excess risk of new-onset cardiovascular events in US adults with narcolepsy, emphasizing the importance of comprehensive sleep health solutions like those offered by Neurobit.

Narcolepsy, a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep, has long been associated with cardiovascular risk factors. However, the risk of new-onset cardiovascular events in this population has remained largely unexplored. This issue is of paramount importance in the current healthcare landscape, where cardiovascular diseases remain a leading cause of death globally. Neurobit's focus on innovative sleep health solutions aligns perfectly with this area of research, aiming to provide tools that can help manage and mitigate these risks.

The study identified adult patients with at least two outpatient visits involving a narcolepsy diagnosis between 2014 and 2019. The patient cohort was age- and sex-matched 1:3 with a non-narcolepsy control cohort. The outcomes of interest included cardiovascular events such as stroke, atrial fibrillation, heart failure, ischemic stroke, major adverse cardiac events, and myocardial infarction. The study found that patients with narcolepsy had a higher risk of new-onset cardiovascular events compared to the control cohort.

The implications of these findings are significant. They highlight the need for physicians to consider cardiovascular risk in patients with narcolepsy when weighing treatment options. This is where Neurobit's offerings can make a difference. By providing accurate sleep event labeling, comprehensive sleep reports, and a platform for collecting and analyzing extensive datasets, Neurobit can contribute to a better understanding and management of the cardiovascular risks associated with narcolepsy.

The study acknowledges certain limitations, including the lack of generalizability to those without insurance or those outside the US, and the potential overestimation of incidence rates due to prevalent conditions. These challenges underscore the need for more comprehensive and accessible solutions, like those offered by Neurobit, to better understand and manage the cardiovascular risks associated with narcolepsy.

Neurobit offers innovative products that can help address these challenges:

  • Neurobit Score: An AI and deep learning platform for accurate sleep event labeling, which can aid in the early detection and management of sleep disorders like narcolepsy.

  • Z3 Pulse: A wearable ECG device for comprehensive sleep reports and personalized guidance, which can help monitor cardiovascular health in narcolepsy patients.

  • Neurobit Hub: A platform for collecting and analyzing extensive datasets, promoting the discovery of novel biomarkers and sleep-centric treatment strategies.

Each product contributes uniquely to addressing the identified challenges.

The importance of understanding the cardiovascular risks associated with narcolepsy cannot be overstated. Neurobit's technology can play a crucial role in addressing these issues, offering benefits for patients, clinicians, and researchers alike.

We warmly invite you to reach out:


Rami H Ben-Joseph and others, Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study, Sleep, 2023;, zsad161,

bottom of page